Alterity Therapeutics launches phase 2 trial of MSA candidate ATH434
Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in patients with multiple system atrophy (MSA). According to the Australian biotech company, the mid-stage clinical trial is now open for patient enrolment in New Zealand. Alterity Therapeutics believes that ATH434 lowers the toxic accumulation of α-synuclein, which […]